In recent years, a staggering 50% decrease in ni

Longevity.

Have you noticed a sudden puffiness or swelling

New study shows that raising levels of fatty aci

On a mission to promote healthier eating habits,

Boosting your lifespan can be as simple as makin

Magnesium is an essential mineral that supports

Longevity.

Imagine struggling to remember simple tasks or f

Summer offers an abundance of delicious foods th

YouthBio Therapeutics has announced what it descr

Transferring regeneration-associated genes from

Company announces PIPE financing of up to $122 m

A recent study published in

Did you know that over

Longevity.

By 2050, over 150 million people could be living

Part of $27 million fund to foster collaboration

New Alzheimer’s drug data highlights increased

A recent study in

Study identifies the nuclear protein Pin1 as piv

Seed round led by SV Health and Two Bear Capital

A new study published in

Recently, there has been a noticeable increase i

Aging impacts everyone, affecting our health and

Longevity.

Rejuvenate Biomed and SAS have announced a collab

Study shows Shingrix vaccine may delay dementia

Cognition Therapeutics reports once-daily drug’s potential to slow Alzheimer’s progression, showing promise with favorable safety profile. Cognition Therapeutics, Inc. recently disclosed findings from their Phase 2 SHINE trial, investigating the efficacy of CT1812, an experimental oral treatment for Alzheimer’s disease. The study, which involved 153 adults with mild-to-moderate Alzheimer’s, assessed the cognitive and functional impacts of daily CT1812 doses over six months, and has reported approximately 40% less cognitive decline in patients administered CT1812 compared with those on a placebo. The SHINE trial, a double-blind, placebo-controlled study, explored two dosages of CT1812 (100mg and 300mg), with the primary objective being the safety and tolerability of the treatment. The drug showed a consistent trend towards cognitive improvement across multiple measures, including an Alzheimer’s Disease Assessment Scale that involved 11 different tasks (ADAS-Cog 11) and a Mini-Mental State Examination based on 11 questions (MMSE). Specifically, by Day 182, participants on placebo experienced a 2.70-point decline on the ADAS-Cog 11 scale, while those on CT1812 showed a lesser decline of 1.66 points – indicating a 39% reduction in cognitive decline in favor of the treatment. Dr Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics, remarked: “A key objective of this trial was to provide…

Arnold Schwarzenegger has significantly boosted

According to registered dietitian and certified

In a recent study published in

Curious about the potential risks and side effec

Herbal remedies have long been used to improve c

Recent study indicates that hyperbaric oxygen th

Recent research highlights a growing concern amo

In a recent revelation that captured public inte

When we think of memory, we often imagine a stat

Imagine you’re striving to boost your health a

Longevity.

New research highlights inconsistency in lifespa

Did you know that during the 2008 Beijing Olympi

A recent study has made headlines for its ground

Keanu Reeves, renowned for his iconic roles in T

Longevity.